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Partial Purification of Topoisomerase I from
Mycobacterium phlei*
Aim: DNA topoisomerases control several cellular activities by catalyzing the relaxation of superhelices, which
are produced during the replication of DNA. Investigation of the inhibitory action of the candidate substances
on topoisomerase activity is widely used in drug development. The purpose of this study was to purify
topoisomerase I from Mycobacterium phlei, which is closely related to Mycobacterium tuberculosis, and
investigate some of its properties.
Materials and Methods: Topoisomerase I from Mycobacterium phlei was partially purified with the method
including homogenization followed by DNase treatment, Sephadex G50 and Heparin Sepharose column
chromatography steps.

1

2

‹hsan Do¤ramac› Children’s Hospital,
Clinical Chemistry Laboratory,
Hacettepe University,
Ankara - TURKEY
Department of Biochemistry
Faculty of Medicine,
Hacettepe University,
Ankara - TURKEY

Results: The enzyme was purified 31.8-fold with a yield of 16.7%. Molecular weight of the enzyme was
estimated to be 125 kDa. Enzyme activity was found to be stable in the pH range of 6.0 - 8.5. ATP and
spermidine were not required for the activity of the enzyme. Camptothecin, which is an inhibitor of eukaryotic
topoisomerase I, did not inhibit the enzyme at the concentrations studied.
Conclusions: The investigated properties of partially purified topoisomerase I from nonpathogenic strain
Mycobacterium phlei were found closely related to those of Mycobacterium tuberculosis. Characterization of
the enzyme that is completely purified with additional purification steps will hopefully lead to the development
of selective antimycobacterial drugs.
Key Words: Mycobacterium phlei, DNA topoisomerase type I, purification, molecular properties

Mycobacterium phlei’den Topoizomeraz I’in K›smen Saflaﬂt›r›lmas›
Amaç: DNA topoizomerazlar DNA’n›n replikasyonu s›ras›nda ortaya ç›kan süpersarmal›n aç›lmas›na arac›
olarak birçok hücresel aktiviteyi kontrol ederler. Topoizomeraz inhibitör etkisinin araﬂt›r›lmas›, yeni ilaç
geliﬂtirilmesinde yayg›n olarak kullan›lan bir yöntem haline gelmiﬂtir. Bu çal›ﬂman›n amac› Mycobacterium
tuberculosis ile yak›n benzerli¤i olan Mycobacterium phlei topoizomeraz I’inin saflaﬂt›r›larak baz› özelliklerinin
incelenmesidir.
Yöntem ve Gereç: Topoizomeraz I Mycobacterium phlei’den sonikasyonu takiben DNaz muamelesi, Sephadex
G50 kromatografisi ve Heparin Sepharose kromatografisi yöntemleri kullan›larak k›smen saflaﬂt›r›lm›ﬂt›r.
Bulgular: Enzim % 16.7 verimle, 31.8 kez saflaﬂt›r›lm›ﬂt›r. Enzimin molekül a¤›rl›¤› 125 kDa olarak tesbit
edilmiﬂtir. Enzim aktivitesinin pH 6.0 - 8.5 aras›nda stabil oldu¤u, aktivite için ATP ve spermidine gerek
duymad›¤› gözlenmiﬂtir. Ökaryotik topoizomeraz I’in inhibitörü olan kamptotesin taraf›ndan, çal›ﬂ›lan
konsantrasyonlarda enzim inhibe edilmemiﬂtir.
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Sonuç: Patojen olmayan Mycobacterium phlei’den k›smen saflaﬂt›r›lan enzimin incelenen özelliklerinin
Mycobacterium tuberculosis’e benzer oldu¤u bulunmuﬂtur. Daha ileri saflaﬂt›rma basamaklar›n›n ard›ndan elde
edilecek enzimin incelenmesi antimikobakteriyel ilaçlar›n geliﬂimine yarar sa¤layabilecektir.
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Introduction

Materials and Methods

DNA topoisomerases control and modify the
topological states of DNA. They are ubiquitous enzymes
catalyzing the relaxation of superhelices produced during
the replication of DNA. Topoisomerases have mainly two
forms (type I and type II). Topoisomerase I breaks a
single DNA strand, while topoisomerase II breaks both
strands and requires ATP for full activity (1-3). In recent
years, topoisomerases gained importance as the target of
several antibacterial and anticancer drugs. Investigation
of the inhibitory action of the candidate substances on
topoisomerase activity is widely used in drug
development (4-7).

Material: Middlebrook 7H9 broth was obtained from
Difco (USA), Heparin Sepharose 6 Fast Flow from
Amersham Biosciences (Uppsala, Sweden), and Sephadex
G50 from Sigma Chemical Company (USA). pBluescript
plasmid was isolated from E. coli XL1-blue strain culture
by alkaline lysis technique and plasmid concentration was
determined spectrophotometrically (21). All other
chemicals were of analytical grade.

Topoisomerase I was purified and studied extensively
from several prokaryotic sources including Escherichia
coli, which is the prototype prokaryotic enzyme (8-9),
Micrococcus luteus (10), Diplococcus pneumoniae (11),
Desulfurococcus
thermophilic
archeabacterium
amylolyticus (12), Fervidobacterium islandicum (13),
Rhodobacter capsulatus (14), Mycobacterium smegmatis
(15,16), and Mycobacterium tuberculosis (17).
According to the World Health Organization (WHO)
global report of 2006, 9 million people are newly
diagnosed with tuberculosis every year (18). In Turkey
18,000 to 20,000 tuberculosis patients have been
reported annually (19). Furthermore, the spread of
multidrug resistant (MDR) strains continuing for decades
worldwide and emergence of a new form termed as
extensively drug resistant (XDR) tuberculosis will worsen
the situation (20). This can only be stopped by discovery
of new drugs. Since those bacteria easily gain resistance
to known antibiotics, the development of new drugs is
urgently needed (20).
This study aimed to purify topoisomerase I from a
nonpathogenic strain, Mycobacterium phlei, and to
investigate some of its properties. Characterization of the
topoisomerase I from Mycobacterium phlei, which has
not been published elsewhere, and comparison of these
properties with the previously published properties of M.
smegmatis and M. tuberculosis enzymes and eukaryotic
topoisomerases may hopefully lead to the development of
selective drugs against tuberculosis, which would
contribute to the solution of an important health
problem.
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Bacterial strain and growth conditions: M. phlei
ATCC 11758 strain was grown in Middlebrook 7H9
broth, supplemented with 0.3% Tween-80, 0.5%
glycerol, 0.005% oleic acid, 0.5% bovine serum albumin
(BSA), 0.2% dextrose, 0.0004% bovine liver catalase,
and 0.085 NaCl for three days at 37°C, with shaking.
Bacteria in the initial log phase (4 days of culture at 37°C
in a shaking incubator) were harvested by centrifugation
at 20,000 x g for 20 min.
DNA topoisomerase activity measurement:
Relaxation activity of DNA topoisomerase I was measured
as described by Stewart and Champoux (22) with some
modifications. The reaction was performed in 20 µl of
reaction mixture containing 40 mM Tris-HCl buffer (pH
8.0), 20 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 50 µg/ml
BSA, 40 µg plasmid DNA and 10 µl of enzyme sample.
Mixtures were incubated at 37°C for 30 min. The
reaction was stopped by the addition of 5 µl
electrophoretic loading solution consisting of 100 mM
EDTA, 60% sucrose, 6% sodium dodecyl sulfate (SDS),
and 0.05% bromophenol blue (pH 8.0).
Agarose gel electrophoresis was used to follow the
enzyme activity (23). The reaction products were
subjected to 1.0% agarose gel electrophoresis in a buffer
consisting of 40 mM Tris, 20 mM glacial acetic acid, and
1 mM EDTA (pH 8.0) at 110 V for 2 h. Gels were stained
with ethidium bromide (1 µg/ml) and photographed
under UV light. Band distribution was analyzed with a
GDS 8000 Complete Gel Documentation and Analysis
System (Gel Works 1D Intermediate, version 2.5; Ultra
Violet Products). The change in the density of the fastest
moving band during the incubation period was used as a
measure of the enzyme activity. At each enzyme
measurement, parallel assays were run with eukaryotic
topoisomerase I of known activity.
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Protein concentration at different stages of
purification was estimated by the Bradford method (24),
using BSA as standard. Polyacrylamide gel electrophoresis
(PAGE) with or without SDS was carried out according to
Laemmli (25).
Unit definition: Known units of eukaryotic
topoisomerase I (Calf thymus, Takara Bio Inc) were used
as a standard for the calculation of the mycobacterial
enzyme activity units. Under the assay conditions,
eukaryotic topoisomerase I activity was linear up to 0.1
units. One unit of eukaryotic topoisomerase I activity was
defined by the producer as the enzyme that completely
relaxes 0.5 µg of supercoiled pBR322 DNA in 50 µl of the
reaction mixture (35 mM Tris-HCl, pH 8.0; 72 mM KCl;
5 mM MgCl2; 5 mM DTT; 5 mM spermidine; 0.01% BSA)
for 30 min at 37°C (http://bio.takara.co.jp).
Purification of topoisomerase I: All steps were
performed at + 4°C and the samples were stored on ice.
The cells were suspended in Buffer A [50 mM Tris-HCl,
pH 8.0, 10% glycerol (w/v)], 50 mM NaCl, 1 mM EDTA,
0.5 mM phenyl methyl sulfonyl fluoride (PMSF), and 10
mM β-mercaptoethanol (ME), and vortexed for 4 x 1 min
with 0.5 mm glass beads (0.5 g/ml). The cells were kept
on ice for 1 min at each interval.
Deoxyribonuclease (DNase) I was added to the
homogenate (0.11 mg of DNase I / ml homogenate) and
the mixture was incubated at + 4°C for 30 min followed
by centrifugation at 20,000 x g for 40 min.
The supernatant was loaded onto a Sephadex G50
column (90 cm x 2.6 cm) equilibrated with Buffer A at a
flow rate of 20 ml/hour. Active fractions were loaded
onto a Heparin Sepharose column (3.0 cm x 2.6 cm)
equilibrated with the same buffer at a flow rate of 10
ml/hour. The column was washed with 130, 50 and 25
ml Buffer A containing 150 mM, 300 mM and 600 mM
NaCl, respectively. Fractions eluted after each step were
combined separately, concentrated and desalted before
measurement of topoisomerase I activity.
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Results

M. phlei topoisomerase I was purified 31.8-fold with
a yield of 16.7%, with a method employing
homogenization followed by DNase I treatment,
Sephadex G50 and Heparin Sepharose column
chromatography steps. Specific activity of the partially
purified enzyme was calculated as 126.32 U/mg (Table ).
Elution profile of Sephadex G50 column is shown in
Figure 1. The enzyme was eluted in the void volume. The
inset shows the relaxation activity of the fractions. Figure
2 shows the elution profile of the Heparin Sepharose
column. Topoisomerase I was eluted from the column at
600 mM NaCl. The activity was assayed after
concentration and desalting of the combined fractions.
The electrophoregram showing the topoisomerase
activities at each step is shown in Figure 3.
Molecular weight of the partially purified enzyme
from M. phlei was estimated to be 125 kDa by SDS PAGE
(Figure 4).
The effect of pH on the enzyme activity was
investigated between pH 7.0 and pH 9.0. The enzyme
activity was quite stable between pH 7.0 and 8.2
(Figure 5).
One mM ATP did not change the activity of the
partially purified enzyme, and the DNA relaxation activity
of the enzyme was not inhibited by 2 mM spermidine and
4.2-42.0 µg camptothecin per unit of enzyme.

Discussion
In this study, partially purified topoisomerase I was
obtained from M. phlei. In the early purification steps,
nuclease activity interfered with the topoisomerase
activity (Figure 3, lanes 2 and 3) and the specific activity
of the homogenate could not be calculated. This has also
been reported by other authors (12,14,26). Specific
activity of the enzyme after Sephadex G50 and Heparin

Table . Purification of M. phlei topoisomerase I.
Purification Step

Sephadex G50
Chromatography
Heparin Sepharose
Chromatography

Volume
(ml)

Protein
(mg/ml)

Total Protein
(mg)

Activity
(U/ml)

Total Activity
(U)

Specific Activity
(U/mg)

Purification
(Fold)

Yield
(%)

35

0.696

24.360

2.76

96.60

3.97

1.0

100.0

6.7

0.019

0.127

2.40

16.08

126.32

31.8

16.7
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Figure 1. Elution profile of Sephadex G50. Column size, 90 cm x 2.6 cm; flow rate, 20 ml/h.
(●): A 280 measurements, (❍): % relative activity. Inset: Relaxation activity of the
fractions. Percentage relative activity was calculated by assigning 100% to the peak
activity.
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Figure 2. Heparin Sepharose column stepwise NaCl elution profile. Column size, 3.0 cm x 2.6
cm; flow rate, 10 ml/hour. ◆: A 280 measurements. Peak III shows topoisomerase I
activity after concentration and desalting. The arrow indicates the starting point of
stepwise NaCl elution.
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Figure 3. Agarose gel electrophoresis of purification steps. Lane 1: plasmid; lane 2: homogenate;
lane 3: homogenate after DNase I incubation; lanes 4,5: peak of Sephadex G50 void;
lane 6: sample loaded onto the Heparin Sepharose column. Lanes 7-9: Heparin
Sepharose column elution with 150 mM, 300 mM and 600 mM NaCl, respectively,
after concentration and desalting. Relaxation assay and electrophoresis were
performed as described in Materials and Methods.
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M

97
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Activity (U/ml)

Figure 4. SDS PAGE analysis of different purification steps. M:
Molecular weight markers: phosphorylase B 97 kDa (1.0 µg),
BSA 66 kDa (1.5 µg), egg albumin 45 kDa (1.5 µg), 29 kDa
carbonic anhydrase (1.0 µg). Lane 1 (5 µg total protein):
homogenate, lane 2 (5 mg total protein): homogenate after
DNase I treatment, lane 3 (5 µg total protein): sample that is
loaded onto Heparin Sepharose column. Lanes 4 (0.8 µg total
protein) and 5 (0.8 µg total protein) indicate Heparin
Sepharose column elutions with 300 mM and 600 mM NaCl,
respectively. The arrow indicates probable topoisomerase I.
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Figure 5. The effect of pH on topoisomerase relaxation activity. The
relaxation activity was assayed in 40 mM Tris-HCl buffer
between pH 7.0 and pH 9.0.

Sepharose chromatography steps was 3.97 and 126.32
U/mg protein, respectively, which makes up a 31.8-fold
purification. Thus, excluding the initial homogenization
step, the overall yield is calculated as 31.8% (Table ).
Total activity of the enzyme after Sephadex G50 and
Heparin Sepharose chromatography steps was 96.60 and
16.08 U, respectively, which gives an overall yield of
16.7% (Table ). The low yield is most likely due to the
presence of bacterial proteases, which gradually degrade
the enzyme.
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Prokaryotic type I topoisomerases have molecular
weights ranging from 75 to 112 kDa (8,12,27,28). The
gene encoding M. tuberculosis topoisomerase I has been
cloned and the molecular weight of the expressed protein
was found to be 99.353 kDa (17). The molecular weight
of the topoisomerase I purified from M. smegmatis was
110 kDa (16), which is similar to our result. On the other
hand, several low molecular weight bands in addition to
the 125 kDa protein were observed in SDS-PAGE (Figure
4, lane: 5). These bands are thought to be the proteolytic
products of the enzyme.
The activity of the partially purified enzyme was stable
over a wide range of pH. It has been reported that M.
smegmatis topoisomerase I activity is also stable in a wide
pH range from 7.0 to 8.5 (15), and our finding is in
agreement.
Type I topoisomerases can relax supercoiled DNA in
the absence of ATP, but type II topoisomerases require
ATP. In our study, partially purified enzyme activity did
not change with the addition of 1 mM ATP to the reaction
mixture. This result is in accordance with the previously
published reports (13-16,28). Prokaryotic type I
topoisomerases do not require ATP for relaxation activity
(22). With this result, we also concluded that the enzyme
was not contaminated with type II topoisomerase.
Spermidine stimulates the relaxation activity of
eukaryotic type I topoisomerases and inhibits E. coli
topoisomerase I relaxation activity (29), but does not
affect the activity of M. smegmatis topoisomerase I (16).
We observed that 2 mM spermidine in the assay mixture
was ineffective on the DNA relaxation activity of partially
purified topoisomerase I from M. phlei, which is closely
related to M. smegmatis.
Camptothecin is an inhibitor of eukaryotic
topoisomerase I, but does not affect the activity of
prokaryotic topoisomerase I. In our study, camptothecin
did not inhibit the partially purified enzyme over a wide
range of concentrations. These results are in agreement
with the published data (16).
This paper describes the preliminary data for
purification of type I topoisomerase from M. phlei.
Further purification and characterization of
mycobacterium topoisomerase I may hopefully lead to the
development of selective antimycobacterial drugs, which
would contribute to the treatment of tuberculosis and to
the solution for this important health problem.
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